Critical Contrast: EXACT Sciences (EXAS) and Geovax Labs (GOVX)

Share on StockTwits

EXACT Sciences (NASDAQ:EXAS) and Geovax Labs (OTCMKTS:GOVX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Institutional & Insider Ownership

91.8% of EXACT Sciences shares are owned by institutional investors. Comparatively, 0.1% of Geovax Labs shares are owned by institutional investors. 3.2% of EXACT Sciences shares are owned by company insiders. Comparatively, 2.1% of Geovax Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


This table compares EXACT Sciences and Geovax Labs’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
EXACT Sciences -35.83% -20.18% -11.11%
Geovax Labs -290.02% N/A -422.86%

Valuation and Earnings

This table compares EXACT Sciences and Geovax Labs’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
EXACT Sciences $265.99 million 40.24 -$114.39 million ($0.99) -87.98
Geovax Labs $1.08 million 5.21 -$2.17 million ($0.03) -0.86

Geovax Labs has lower revenue, but higher earnings than EXACT Sciences. EXACT Sciences is trading at a lower price-to-earnings ratio than Geovax Labs, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

EXACT Sciences has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Comparatively, Geovax Labs has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for EXACT Sciences and Geovax Labs, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EXACT Sciences 0 2 10 0 2.83
Geovax Labs 0 0 0 0 N/A

EXACT Sciences currently has a consensus price target of $89.90, suggesting a potential upside of 3.21%. Given EXACT Sciences’ higher probable upside, research analysts plainly believe EXACT Sciences is more favorable than Geovax Labs.


EXACT Sciences beats Geovax Labs on 9 of the 13 factors compared between the two stocks.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Geovax Labs Company Profile

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines for infectious diseases and cancer in the United States and internationally. The company through its patented Modified Vaccinia Ankara-Virus Like Particle vaccine platform develops various vaccines. It is developing various vaccines that are in human clinical trials, and preclinical research and development phases, including vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; United States Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; Peking University; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with's FREE daily email newsletter.

Leave a Reply